Karyopharm Therapeutics Inc Cash Flow Reinvestment Rate

Latest as of December 2021: 1.20x

Karyopharm Therapeutics Inc cash flow reinvestment rate. Karyopharm Therapeutics Inc (KPTI) has a Cash Flow Reinvestment Rate of 1.20x as of December 2021, reinvesting $30.68 Million (capex $207.00K plus investments $30.48 Million) from operating cash flow of $25.48 Million. Explore cash flow to debt ratio of Karyopharm Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

1.20x

(Capex + Investments) / Operating CF

Total Reinvested

$30.68 Million

Capex + Investments

Operating Cash Flow

$25.48 Million

USD

Capital Expenditures

$207.00K

USD

Karyopharm Therapeutics Inc Cash Flow Reinvestment Rate by Year (None–None)

Karyopharm Therapeutics Inc cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Karyopharm Therapeutics Inc. For the full cash flow conversion analysis, see KPTI cash generation efficiency.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow